# AALL0434 (NCT00408005)

> Combination Chemotherapy in Treating Young Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or T-cell Lymphoblastic Lymphoma

No report yet. It can be ordered.

- Indication: newly diagnosed T-cell acute lymphoblastic leukemia or lymphoma

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT00408005
- Phase: PHASE3
- Status: COMPLETED
- Sponsor: National Cancer Institute (NCI)
- Conditions: T Acute Lymphoblastic Leukemia; T Lymphoblastic Lymphoma
- Interventions: Asparaginase; Cyclophosphamide; Cytarabine; Daunorubicin Hydrochloride; Dexamethasone; Doxorubicin Hydrochloride; Laboratory Biomarker Analysis; Leucovorin Calcium; Mercaptopurine; Methotrexate; Nelarabine; Pegaspargase; Prednisone; Radiation Therapy; Thioguanine; Vincristine Sulfate
- Enrollment: 1895
- Primary outcome: Disease-free Survival (DFS) for Randomized Nelarabine T-ALL Cohort (Arm I vs. Arm II vs. Arm III vs. Arm IV)
- Primary outcome: Disease-free Survival (DFS) for Randomized Nelarabine T-ALL Cohort (Arm I + Arm III vs. Arm II + Arm IV)
- Primary outcome: Disease-free Survival (DFS) for Randomized Methotrexate T-ALL Cohort (Arm I vs. Arm II vs. Arm III vs. Arm IV)
- Primary outcome: Disease-free Survival (DFS) for Randomized Methotrexate T-ALL Cohort (Arm I + Arm II vs. Arm III + Arm IV)
- Primary outcome: Disease-free Survival (DFS) for T-cell Lymphoblastic Lymphoma (T-LLy) Cohort

## Indexed commentary on AALL0434 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- X threads: 3

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=aall0434-nct00408005